I still insist that patents that are filed as a result of collaborations with PS Targeting and learning new facts, new knowledge .....that IS NOT common knowledge ..etc etc may have to give some rights back to Peregrine and I hope Peregrine can see whom they gave PS Targeting info to and patents filed soon after must be monitored ...and questioned how such info would be known if it were not for PS Targeting knowledge and seeing which BIOMARKERS to concentrate on...etc
I am not saying this patent below falls into this but interesting filed April and published soon after.... _____________________
Epigenetic Markers for the Identification of Blood Sub-cells of Type 1 Publication number: 20170233807 Abstract: The present invention relates to a method, in particular an in vitro method, for identifying CD3CD4 positive T lymphocytes of a mammal, wherein said method comprises analysing the methylation status of at least one CpG position in the CD3a/b/c/d/g genes, in particular their “upstream” regulatory regions, and in particular the promoter and other conserved regions of the gene cd3, wherein a demethylation of at least one CpG in the analyzed sample to at least 90% is indicative for memory and naive CD4 or/and memory and/or naïve T lymphocytes. Furthermore, the present invention is directed at the use of DNA-methylation analysis of the genes CD3a/b/c/d for the detection and quality assurance and control of T lymphocytes. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof. Type: Application Filed: April 3, 2017 Publication date: August 17, 2017 Inventors: Sven OLEK, Ivana TÜRBACHOVA - deceased